Royal Bank Of Canada Relay Therapeutics, Inc. Transaction History

Royal Bank Of Canada

$422 Billion
Q1 2024

A detailed history of Royal Bank Of Canada transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 2,122 shares of RLAY stock, worth $13,495. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,122

Previous 27,797 92.37%

Holding current value

$13,495

Previous $306,000 94.44%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$7.5 - $12.07 $192,562 - $309,897	-25,675 Reduced 92.37%	2,122 $17,000
Q4 2023 Feb 14, 2024	BUY	$6.01 - $11.48 $75,960 - $145,095	12,639 Added 83.38%	27,797 $306,000
Q3 2023 Nov 14, 2023	BUY	$8.24 - $12.97 $47,281 - $74,421	5,738 Added 60.91%	15,158 $127,000
Q2 2023 Aug 14, 2023	BUY	$9.99 - $18.27 $45,973 - $84,078	4,602 Added 95.52%	9,420 $118,000
Q1 2023 May 15, 2023	SELL	$15.0 - $22.76 $144,480 - $219,224	-9,632 Reduced 66.66%	4,818 $79,000

Q4 2022 Feb 14, 2023	BUY	$14.16 - $24.02 $186,388 - $316,175	13,163 Added 1022.77%	14,450 $215,000
Q3 2022 Nov 14, 2022	BUY	$18.07 - $31.37 $15,467 - $26,852	856 Added 198.61%	1,287 $29,000
Q2 2022 Aug 15, 2022	SELL	$13.31 - $34.88 $51,483 - $134,915	-3,868 Reduced 89.97%	431 $7,000
Q1 2022 May 16, 2022	SELL	$20.26 - $32.36 $535,451 - $855,242	-26,429 Reduced 86.01%	4,299 $129,000
Q4 2021 Feb 14, 2022	BUY	$26.0 - $37.03 $301,028 - $428,733	11,578 Added 60.46%	30,728 $944,000
Q3 2021 Nov 15, 2021	BUY	$29.75 - $37.99 $446,160 - $569,736	14,997 Added 361.11%	19,150 $605,000
Q2 2021 Aug 16, 2021	BUY	$27.5 - $38.19 $114,207 - $158,603	4,153 New	4,153 $152,000

Others Institutions Holding RLAY

# of Institutions

188

Shares Held

127M

Call Options Held

4.2K

Put Options Held

1.7K

View Full List

About Relay Therapeutics, Inc.

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $765M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

More about RLAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Relay Therapeutics, Inc. Transaction History